

BactiVac Network Management Oversight Board (NMOB)

Terms of Reference

Overall remit:

The BactiVac Network Oversight Management Board (NMOB) is responsible for devising and reviewing BactiVac Network strategy, making decisions related to its implementation, based on recommendations from the Operations Management Group and input from the Full Membership.

Terms of Reference:

1. To advise and support the Directors of the BactiVac Network in the strategic management and leadership of the network
2. To agree the plan for the establishment and delivery of the network, including the dissemination of information, encouraging widespread, open membership
3. To facilitate communication and ensure the effective co-ordination of all matters relevant to the running of the BactiVac Network and its activities, including interactions with other appropriate national and international organisations
4. To monitor the network's performance against all relevant targets and benchmarks, identifying action to encourage continuous improvement
5. To approve the distribution and awarding of network funding, including reviewing applications submitted for funding under the network's catalyst schemes
6. To have oversight over the commissioning of the two scoping exercises to address important knowledge gaps in bacterial vaccinology and utilise the findings, as appropriate, to guide the network's future strategy
7. To review BactiVac Network's risk register, including identification of action required to mitigate threats and to exploit opportunities

Duties of members of the Management Oversight Board:

- To act in the best interests of the BactiVac Network
- To take collective responsibility for implementation of the Management Oversight Board's decisions
- To act in good faith and with integrity
- To exercise due care and diligence
- To disclose and avoid any conflicts of interest
- To respect the confidentiality of those matters so classified
- Not to use their position to gain advantage for themselves or others
- Members are also expected to observe the 7 principles of public life identified by the Committee on Standards in Public Life (the Nolan Committee): selflessness, integrity, objectivity, accountability, openness, honesty, leadership.

Membership:

The constitution of the NMOB will be reviewed on an annual basis and revised, if required, based on the needs of the network in relation to any additional expertise required to successfully deliver the network's strategy. The expectation is that members of the NMOB will actively engage with the Network and attend a minimum of one meeting each year. The tenure of membership is for the duration of the current funding of the funding period i.e. until 31/03/23.

| Name | Position | Institution/Company | Expertise |
|--|--|---|--|
| Calman MacLennan (Chair) | Professor of Vaccine Immunology | University of Birmingham | Human immunology, Bacterial vaccines |
| Adam Cunningham | Professor of Functional Immunology | University of Birmingham | Functional immunology, Mouse models |
| Constantino Lopez-Macias | Professor | National Medical Centre, Mexico City | Vaccine development in Latin America |
| Seanette Wilson | Science and Innovation Leader | Biovac Institute, Cape Town, South Africa | LMIC Vaccine Industry, DCVM |
| John McGiven | Senior Scientific Officer | APHA | Veterinary vaccines and diagnostics |
| Anthony Scott | Director | Vaccine Centre, LSHTM, London | Vaccine and Infection Epidemiology |
| Andrew Pollard | Director | Oxford Vaccine Group, University of Oxford | Vaccines, Challenge studies, Paediatrics |
| Alex Richter | Professor of Clinical Immunology | University of Birmingham | Vaccine responses in Secondary Immunodeficiency |
| Georgina Drury | Programme Lead, UKRI Future Leaders Fellowships Team | UK Research and Innovation (UKRI) | Science policy, research development and support |
| Jo Dean | BactiVac Network Operations Manager | University of Birmingham | Operational and project management |
| Roma Chilengi | Chief Scientific Officer and Head of Enteric Disease | Centre for Infectious Disease Research in Zambia | Enteric diseases vaccines, clinical trials in Africa |
| Stephen Baker | Director of Research for Global Health | University of Cambridge | Enteric infections research |
| Faith Osier | Executive Director | IAVI Human Immunology Laboratory, Imperial College London | Vaccine development, mechanisms of immunity |
| Birgitte Giersing* *Observer status | Technical Officer | World Health Organisation | Vaccine development and delivery |
| Francesca Micoli | Head of Technology Platform Unit | GSK Vaccines Institute for Global Health, Siena, Italy | Vaccine development and delivery |
| Ankur Mutreja | Senior Manager | Coalition for Epidemic Preparedness Innovations (CEPI) | Conjugate, vesicle and whole cell killed vaccines, antibodies, mucosal immunology |
| Elizabeth Klemm | Senior Scientific Manager | Novo Nordisk Foundation | Research development, host-pathogen interactions, global health and infectious disease |
| Mark Stevens | Professor of Microbial Pathogenesis | The Roslin Institute | Salmonella, E. coli and Campylobacter infections, pathogenesis and protection |
| Matt O'Shea | Consultant in Infectious Diseases and Clinical | University of Birmingham, UK | Infectious diseases and tropical medicine |

| Name | Position | Institution/Company | Expertise |
|-------------------------|--|--|--|
| | Microbiology & Senior Lecturer in Defence Pathology | | |
| Kristen Albright | Chief Executive Officer | Prokarium Ltd | Translational development of early and late stage therapeutics for vaccines |
| Xin Tong | R&D Director | Walvax Biotechnology Co Ltd, China | Vaccine manufacture |
| Jeremy Salt | Chief Executive Officer | The Vaccine Group | Veterinary vaccines, technical development & Manufacturing, clinical trials, tropical medicine |
| V.Krishna Mohan | Executive Director | Bharat Biotech International, India | Vaccine manufacture |
| Adrian Shields | Clinical Lecturer | University of Birmingham | Clinical immunology and antibody response |

***Observer status** - An individual who is permitted to attend and participate in meetings of the board of directors and to receive all information provided to members of the management oversight board (including minutes of board meetings), but who is not permitted to formally vote on matters submitted for a vote.

The Management Oversight Board may invite any person to attend its meetings, subject to the approval of the Chair of the Board.

Administrative support

- Susan Pope, BactiVac Network Administrator
- Evelina Balandyte-Shergill, BactiVac Network Administrator
- *Vacancy*, BactiVac Network Communications Officer

Frequency of meetings:

The Management Oversight Board will meet quarterly, with the aim of holding 2 meetings face to face each year (one of which will be the Annual Network Meeting).